Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

被引：0
|
作者：
E. Claire Dees
Jeffrey R. Infante
Roger B. Cohen
Bert H. O’Neil
Suzanne Jones
Margaret von Mehren
Hadi Danaee
Yih Lee
Jeffrey Ecsedy
Mark Manfredi
Katherine Galvin
Bradley Stringer
Hua Liu
Omar Eton
Howard Fingert
Howard Burris
机构：
[1] University of North Carolina,UNC Lineberger Comprehensive Cancer Center
[2] Sarah Cannon Research Institute,undefined
[3] Fox Chase Cancer Center,undefined
[4] Millennium Pharmaceuticals,undefined
[5] Inc.,undefined
[6] Forest Research Institute,undefined
[7] Inc.,undefined
[8] Boston University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
MLN8054; Aurora A kinase; Dose-limiting toxicity; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 954
页数：9
相关论文
共 50 条
  • [31] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Mross, Klaus
    Richly, Heike
    Frost, Annette
    Scharr, Dirk
    Nokay, Bahar
    Graeser, Ralph
    Lee, Chooi
    Hilbert, James
    Goeldner, Rainer-George
    Fietz, Oliver
    Scheulen, Max E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 405 - 417
  • [32] Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
    Graff, Julie N.
    Higano, Celestia S.
    Hahn, Noah M.
    Taylor, Matthew H.
    Zhang, Bin
    Zhou, Xiaofei
    Venkatakrishnan, Karthik
    Leonard, E. Jane
    Sarantopoulos, John
    CANCER, 2016, 122 (16) : 2524 - 2533
  • [33] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Dittrich, Christian
    Fridrik, Michael A.
    Koenigsberg, Robert
    Lee, Chooi
    Goeldner, Rainer-Georg
    Hilbert, James
    Greil, Richard
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 409 - 422
  • [34] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Christian Dittrich
    Michael A. Fridrik
    Robert Koenigsberg
    Chooi Lee
    Rainer-Georg Goeldner
    James Hilbert
    Richard Greil
    Investigational New Drugs, 2015, 33 : 409 - 422
  • [35] Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237
    Sloane, Dominic A.
    Trikic, Michael Z.
    Chu, Matthew L. H.
    Lamers, Maria B. A. C.
    Mason, Clive S.
    Mueller, Ilka
    Savory, Wendy J.
    Williams, David H.
    Eyers, Patrick A.
    ACS CHEMICAL BIOLOGY, 2010, 5 (06) : 563 - 576
  • [36] Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
    Falchook G.S.
    Zhou X.
    Venkatakrishnan K.
    Kurzrock R.
    Mahalingam D.
    Goldman J.W.
    Jung J.A.
    Ullmann C.D.
    Milch C.
    Rosen L.S.
    Sarantopoulos J.
    Drugs in R&D, 2016, 16 (1) : 45 - 52
  • [37] ABSORPTION, METABOLISM, AND EXCRETION OF ALISERTIB (MLN8237), AN AURORA A KINASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Liao, Mingxiang
    Yang, Johnny
    Chong, Saeho
    Venkatakrishnan, Karthik
    Chowdhury, Swapan
    DRUG METABOLISM REVIEWS, 2015, 47 : 195 - 195
  • [38] A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
    Davis, S. Lindsey
    Lam, Elaine T.
    Corr, Bradley R.
    O'Bryant, Cindy L.
    Glode, Ashley
    Adler, Nichole
    Pitts, Todd M.
    Tentler, John J.
    Capasso, Anna
    Dailey, Kyrie
    Serkova, Natalie J.
    Weekes, Colin D.
    Gustafson, Daniel L.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Leong, Stephen
    Eckhardt, S. Gail
    Diamond, Jennifer R.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [39] MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy
    Hoar, Kara
    Chakravarty, Arijit
    Rabino, Claudia
    Wysong, Deborah
    Bowman, Douglas
    Roy, Natalie
    Ecsedy, Jeffrey A.
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (12) : 4513 - 4525
  • [40] Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
    Steeghs, Neeltje
    Eskens, Ferry A. L. M.
    Gelderblom, Hans
    Verweij, Jaap
    Nortier, Johan W. R.
    Ouwerkerk, Jan
    van Noort, Conny
    Mariani, Mariangela
    Spinelli, Riccardo
    Carpinelli, Patrizia
    Laffranchi, Bernard
    de Jonge, Maja J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5094 - 5101
12345